T cell response to oncoprotein E7 of Human Papillomavirus genotype 16 (HPV 16) delivered by Salmonella typhi strain Ty21a (S. typhi Ty21a) in mice.
作者： M Lakshmi Narasu , Rajan Sriraman , K. Sathish , VA Srinivasan , K. Balaji
DOI:
关键词: ELISPOT 、 Splenocyte 、 Immunotherapy 、 Expression vector 、 Virology 、 Recombinant DNA 、 Ty21a 、 T cell 、 Salmonella typhi 、 Medicine
摘要: Immunotherapy is intensely being considered for either a stand-alone or supplemental treatment of HPV associated precancers and cancers. The aim the study was to enquire whether S. typhi Ty21a engineered express 16 E7 (Ty21a-E7) elicits T cell response oncoprotein. codon optimized synthetic HPV16 gene cloned in an expression vector under constitutive promoter (Ptac). Female mice strain C57BL/6 were immunized intra nasally with Ty21a-E7. mediated immune evaluated employing IFNγ-Elispot assay. Splenocytes stimulated affinity purified recombinant proteins, GST-E7 GST expressed E. coli BL21. specific IFN secreting- spot forming cells (SFCs) obtained on stimulation Elispot assay 240 (±6.92) cells/million splenocytes, significantly higher (p< 0.01) than number splenocytes (67.3 ±26.40 cells/million). antigen found be predominantly CD4+ type. results show CMI mouse model study. To our knowledge this first reporting oncoprotein delivered by Ty21a- live-attenuated, oral, typhoid vaccine strain.
参考文章(26)
Alexander E. Kalyuzhny, Chemistry and biology of the ELISPOT assay. Methods of Molecular Biology. ,vol. 302, pp. 15- 31 ,(2005) , 10.1385/1-59259-903-6:015
Sylvia Janetzki, Josephine H. Cox, Neal Oden, Guido Ferrari, Standardization and validation issues of the ELISPOT assay. Methods of Molecular Biology. ,vol. 302, pp. 51- 86 ,(2005) , 10.1385/1-59259-903-6:051
M A Stanley, Immune responses to human papilloma viruses. Indian Journal of Medical Research. ,vol. 130, pp. 266- 276 ,(2009)
Nicholas Coleman, Humphrey D.L. Birley, Adrian M. Renton, Nashat F. Hanna, Balvinder K. Ryait, Micheline Byrne, David Taylor-Robinson, Margaret A. Stanley, Immunological events in regressing genital warts. American Journal of Clinical Pathology. ,vol. 102, pp. 768- 774 ,(1994) , 10.1093/AJCP/102.6.768
Ivaylo Gentschev, Simone Spreng, Heike Sieber, Jose Ures, Fabian Mollet, Andre Collioud, Jon Pearman, Monika E. Griot-Wenk, Joachim Fensterle, Ulf R. Rapp, Werner Goebel, Simon A. Rothen, Guido Dietrich, Vivotif® – A ‘Magic Shield’ for Protection against Typhoid Fever and Delivery of Heterologous Antigens Chemotherapy. ,vol. 53, pp. 177- 180 ,(2007) , 10.1159/000100515
Harald zur Hausen, Papillomaviruses in the causation of human cancers — a brief historical account Virology. ,vol. 384, pp. 260- 265 ,(2009) , 10.1016/J.VIROL.2008.11.046
Gary Clifford, Silvia Franceschi, Mireia Diaz, Nubia Muñoz, Luisa Lina Villa, None, Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases Vaccine. ,vol. 24, pp. S26- S34 ,(2006) , 10.1016/J.VACCINE.2006.05.026
E VALLIKAD, Cervical Cancer: The Indian Perspective International Journal of Gynecology & Obstetrics. ,vol. 95, ,(2006) , 10.1016/S0020-7292(06)60037-4
Jun-Han Su, Anjui Wu, Elizabeth Scotney, Barbara Ma, Archana Monie, Chien-Fu Hung, T.-C. Wu, Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs. ,vol. 24, pp. 109- 129 ,(2010) , 10.2165/11532810-000000000-00000
Andrew Gray, Adam B. Raff, Maurizio Chiriva-Internati, Si-Yi Chen, W. Martin Kast, A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunological Reviews. ,vol. 222, pp. 316- 327 ,(2008) , 10.1111/J.1600-065X.2008.00605.X